Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS).
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
received:
17
05
2020
accepted:
28
10
2020
entrez:
10
2
2021
pubmed:
11
2
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Monoclonal gammopathy of undetermined significance (MGUS) is rare in young patients (age <40 years at diagnosis), with a prevalence of <0.3%, representing ~2% of all patients with MGUS. We hypothesized that MGUS detected in young patients may be associated with a higher risk of progression. We examined 249 patients with MGUS < 40 years old. Among these, 135 patients had immune-related conditions, including infections, autoimmune and inflammatory disorders at the time of diagnosis of MGUS. The risk of progression to multiple myeloma or a related disorder at 5 years and 10 years was 6.0% and 13.8%, respectively. The size of M protein was a significant risk factor for progression (HR 4.2, 95% CI 2.2-7.9). There was a trend that the risk of progression was higher in patients without immune-related conditions (HR 2.36, 95% CI 0.85-6.52, p = 0.088). The M protein resolved in 36 (14%) patients, with a greater likelihood of resolution in patients with immune-related conditions (RR 1.9, 95% CI 1.02-3.6). Young patients with MGUS have a similar risk of progression as older patients, 1.4% per year. Over 50% are diagnosed in the setting of immune-related disorders. Patients with immune-related disorders may have a lower risk of progression.
Identifiants
pubmed: 33563898
doi: 10.1038/s41408-021-00406-6
pii: 10.1038/s41408-021-00406-6
pmc: PMC7873268
doi:
Substances chimiques
Myeloma Proteins
0
multiple myeloma M-proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26Subventions
Organisme : NCI NIH HHS
ID : P50 CA186781
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA107476
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA168762
Pays : United States
Références
N Engl J Med. 2006 Mar 30;354(13):1362-9
pubmed: 16571879
Blood. 2009 May 28;113(22):5412-7
pubmed: 19179464
Am J Clin Pathol. 2012 Oct;138(4):609-13
pubmed: 23010717
Cancer Chemother Rep. 1962 Feb;16:257-9
pubmed: 14470881
Blood. 2008 Aug 15;112(4):1338-45
pubmed: 18515658
Blood. 2013 Apr 25;121(17):3413-9
pubmed: 23435460
Oncotarget. 2017 Nov 15;8(63):106333-106341
pubmed: 29290952
Haematologica. 2010 Oct;95(10):1730-7
pubmed: 20511669
Rev Clin Esp. 2008 Jun;208(6):288-94
pubmed: 18620653
J Natl Cancer Inst. 1968 Sep;41(3):665-81
pubmed: 5677315
BBA Clin. 2016 May 25;6:12-8
pubmed: 27331023
Leukemia. 2014 Feb;28(2):384-390
pubmed: 23817176
Clin Rheumatol. 2010 Nov;29(11):1323-6
pubmed: 20213125
Clin Chem Lab Med. 2018 Nov 27;56(12):e310-e312
pubmed: 29902154
Blood. 2008 Apr 1;111(7):3388-94
pubmed: 18239085
Blood Cancer J. 2017 Oct 20;7(10):e618
pubmed: 29053158
N Engl J Med. 2018 Jan 18;378(3):241-249
pubmed: 29342381
J Hematol Oncol. 2012 Oct 02;5:59
pubmed: 23031386
N Engl J Med. 2002 Feb 21;346(8):564-9
pubmed: 11856795
Colorectal Dis. 2019 Jul;21(7):775-781
pubmed: 30848537
Ann Biol Clin (Paris). 2015 Mar-Apr;73(2):185-9
pubmed: 25847741
Nat Rev Cancer. 2012 Apr 12;12(5):335-48
pubmed: 22495321
Ann Hematol. 2019 Jan;98(1):19-28
pubmed: 30073393
Blood. 2011 Dec 8;118(24):6284-91
pubmed: 21998210
Clin Rheumatol. 2018 Jul;37(7):1751-1762
pubmed: 29532268
Hum Pathol. 2018 May;75:154-158
pubmed: 29180248
Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):332-42
pubmed: 24451437